NOKOMIS, Fla.--(BUSINESS WIRE)--

With the global demand for biotechnology solutions to mounting health concerns growing every day, Rainbow Coral Corp. (OTCBB: RBCC.OB - News) has been working hard to deliver the kinds of breakthroughs that doctors, scientists, and researchers the world over are begging for.

Today, Rainbow BioSciences, the biotech division of Rainbow Coral Corp. (OTCBB: RBCC.OB - News) announced that it has signed a deal to acquire an interest in the cutting-edge biotech firm Nano3D Biosciences, Inc. (n3D). One of the hottest emerging biotech developers in the world, n3D is producing new tools that could challenge long-held assumptions about healthcareand change lives in the process.

The agreement is the culmination of months of work and negotiations. N3D is a terrific fit with RBCCs aggressive focus on company growth. The companys new breakthrough cell-culturing technology, the Bio-Assembler, is fully commercialized already. RBCCs participation will provide n3D with the funds for marketing and distributing the Bio-Assembler to new markets as cellular research in the biotech sector explodes around the globe.

The acquisition has RBCC well-positioned to participate in the potentially dramatic upside that many bioscience companies realize at this stage. N3Ds Bio-Assembler could be poised to revolutionize the way stem cell research and the study of other living tissues is conducted worldwide, with the potential to ultimately reduce the development timeline for new life-saving drug therapies.

For more information on Rainbow BioSciences, RBCCs biotechnology division, please visit http://www.rainbowbiosciences.com/investors.

Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Cell Therapeutics, Inc. (NASDAQ: CTIC - News), Biogen Idec Inc. (NASDAQ: BIIB - News), Abbott Laboratories (NYSE: ABT - News) and Elan Corp. (NYSE: ELN - News).

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC.OB - News). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.RainbowBioSciences.com]. For investment information and performance data on the company, please visit http://www.RainbowBioSciences.com/investors.

Notice Regarding Forward-Looking Statements

View original post here:
RBCC Closes Deal with Game Changing Biotech Firm